Oral fluorescein angiography: reassessment of its relative safety and evaluation of optimum conditions with use of capsules.

Oral fluorescein angiography: reassessment of its relative safety and evaluation of optimum conditions with use of capsules. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Oral fluorescein angiography: reassessment of its relative safety and evaluation of optimum conditions with use of capsules. Abstract Text:

Injection of fluorescein intravenously for fundal angiography is associated with a high incidence of minor adverse effects (21%) but a very low incidence of serious (life threatening) reactions (0.05%). A serious reaction may occur without warning in a patient with no history of atopy. There are no reports of oral fluorescein causing a serious reaction, and minor adverse effects are uncommon. A study was undertaken to determine optimum conditions for oral fluorescein angiography. Capsules proved more convenient than a solution for ingestion of fluorescein. A dose of 25 mg/kg body weight produced good quality angiograms in 75% of the patients. The best pictures were obtained by photographing the fundus after 40 and 60 minutes.

Oral fluorescein angiography: reassessment of its relative safety and evaluation of optimum conditions with use of capsules. Publishing Authors By Initials

For similar health care economics and organizations: technology assessment, biomedical research abstracts see: health care economics and organizations: technology assessment, biomedical research

PUBMED ID PMID:

MEDLINE DATE:

Oral fluorescein angiography: reassessment of its relative safety and evaluation of optimum conditions with use of capsules. Journal Published:

PUBLICATION TYPE: Randomized Controlled Trial

Journal: The British journal of ophthalmology

VOLUME: 74

Page Numbers: 458-61

Journal Abbreviation: Br J Ophthalmol

ISSN: 0007-1161

DAY: 28

MONTH: Aug

YEAR: 1990

Oral fluorescein angiography: reassessment of its relative safety and evaluation of optimum conditions with use of capsules. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 421041

Oral fluorescein angiography: reassessment of its relative safety and evaluation of optimum conditions with use of capsules. Keywords Mesh Terms:

KEYWORDS: Technology Assessment, Biomedical

MESH TERMS: diagnostic use

Chemical & Substance for Abstract: Oral fluorescein angiography: reassessment of its relative safety and evaluation of optimum conditions with use of capsules. Information

Substance Name: Fluorescein

Registry Number: 2321-07-5

Grant and Affiliation Information for Oral fluorescein angiography: reassessment of its relative safety and evaluation of optimum conditions with use of capsules.

AFFILIATION: District General Hospital, Southport, Merseyside.

Country: ENGLAND

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Br J Ophthalmol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Oral fluorescein angiography: reassessment of its relative safety and evaluation of optimum conditions with use of capsules Related Publications

• A 29-year-old man with subcutaneous emphysema of the neck following blunt trauma.
• A web portal that enables collaborative use of advanced medical image processing and informatics tools through the Biomedical Informatics Research Network (BIRN).
• Acute rejection in HCV-infected liver transplant recipients: The great conundrum.
• Are stem cells drugs? The regulation of stem cell research and development.
• ArsD residues Cys12, Cys13, and Cys18 form an As(III)-binding site required for arsenic metallochaperone activity.
• BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing.
• Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair.
• Critical role for Ebf1 and Ebf2 in the adipogenic transcriptional cascade.
• Diagnosis and management of laryngopharyngeal reflux disease.
• Distinct roles of fibroblast growth factor receptor 1 and 2 in regulating cell survival and epithelial-mesenchymal transition.
• Ectopic induction of tendon and ligament in rats by growth and differentiation factors 5, 6, and 7, members of the TGF-beta gene family.
• Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues.
• Fibroblast growth factor-10 prevents H2O2-induced cell cycle arrest by regulation of G1 cyclins and cyclin dependent kinases.
• Formation of eosinophilic and monocytic intradermal inflammatory sites in the dog by injection of human RANTES but not human monocyte chemoattractant protein 1, human macrophage inflammatory protein 1 alpha, or human interleukin 8.
• Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis.
• I(Kr) contributes to the altered ventricular repolarization that determines long-term cardiac memory.
• Identification of genes that modulate sensitivity of U373MG glioblastoma cells to cis-platinum.
• Induction, characterization, and functional coupling of the high affinity chemokine receptor for RANTES and macrophage inflammatory protein-1 alpha upon differentiation of an eosinophilic HL-60 cell line.
• Integration is as essential as balance.
• Integration of prolactin and glucocorticoid signaling at the beta-casein promoter and enhancer by ordered recruitment of specific transcription factors and chromatin modifiers.
• Linking cost sharing to value: an unrivaled yet unrealized public health opportunity.
• Long-term cardiac memory in canine heart is associated with the evolution of a transmural repolarization gradient.
• Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence.
• Mapping pathways downstream of sphingosine 1-phosphate subtype 1 by differential chemical perturbation and proteomics.
• Measuring the activities of the Sulfs: two novel heparin/heparan sulfate endosulfatases.
• Mouse and human granzyme B have distinct tetrapeptide specificities and abilities to recruit the bid pathway.
• Pre-clinical testing of a phased array ultrasound system for MRI-guided noninvasive surgery of the brain--a primate study.
• Stop! In the name of transforming growth factor-beta: keeping estrogen receptor-alpha-positive mammary epithelial cells from proliferating.
• Sulfated L-selectin ligands as a therapeutic target in chronic inflammation.
• The effects of aging on the bone inductive activity of recombinant human bone morphogenetic protein-2.